Last updated on July 2018

Tisotumab Vedotin (HuMax -TF-ADC) Safety Study in Patients With Solid Tumors

Brief description of study

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) in a mixed population of patients with specified solid tumors

Detailed Study Description

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of tisotumab vedotin (HuMax-TF-ADC) as determined in Part 1

Clinical Study Identifier: NCT02552121

Contact Investigators or Research Sites near you

Start Over

David S Hong, MD

MD Anderson Cancer Center
Houston, TX United States

Joseph Kerger, MD

Institut Jules Bordet
Bruxelles, Belgium

Nicole Concin, MD

Universitaire Ziekenhuizen Leuven
Leuven, Belgium

Jean-Luc Canon, MD

Grand H pital de Charleroi
Charleroi, Belgium

Christine Gennigens, MD

CHU de Li ge
Liege, Belgium

Lionel D'Hondt, MD

CHU UCL Namur - site Godinne
Yvoir, Belgium

Jean-François Baurain, MD

Cliniques Universitaires Saint-Luc
Brussels, Belgium

Peter Vuylsteke, MD

CHU UCL Namur - Sainte Elisabeth
Namur, Belgium

Ulrik Lassen, MD

Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark

Tamás Pintér, MD

Petz Alad r Megyei Oktat K rh z
Gyor, Hungary

Róbert Póka, MD

Debreceni Egyetem Klinikai K zpont
Debrecen, Hungary

Magdolna Dank, MD

Semmelweis Egyetem Onkol giai K zpont
Budapest, Hungary

Rebecca Kristeleit, MD

University College London Hospitals NHS Foundation Trust
London, United Kingdom

Hendrik-Tobias Arkenau, MD

Sarah Cannon Cancer Center
London, United Kingdom

Emma Dean, MD

The Christie NHS Foundation Trust
Manchester, United Kingdom

Johann de Bono, Professor

The Royal Marsden NHS Foundation Trust
Sueery, United Kingdom